Analysts’ Weekly Ratings Updates for BioMarin Pharmaceutical (BMRN)

A number of research firms have changed their ratings and price targets for BioMarin Pharmaceutical (NASDAQ: BMRN):

• 5/5/2026 – BioMarin Pharmaceutical had its price target lowered by Sanford C. Bernstein from $94.00 to $82.00. They now have an “outperform” rating on the stock.
• 5/5/2026 – BioMarin Pharmaceutical had its price target lowered by Morgan Stanley from $120.00 to $119.00. They now have an “overweight” rating on the stock.
• 5/5/2026 – BioMarin Pharmaceutical had its “sector perform” rating reaffirmed by Royal Bank Of Canada. They now have a $66.00 price target on the stock.
• 5/5/2026 – BioMarin Pharmaceutical had its “neutral” rating reaffirmed by HC Wainwright. They now have a $55.00 price target on the stock.
• 5/1/2026 – BioMarin Pharmaceutical was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 4/27/2026 – BioMarin Pharmaceutical is now covered by Morgan Stanley. They set an “overweight” rating and a $120.00 price target on the stock.
• 4/16/2026 – BioMarin Pharmaceutical was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 3/31/2026 – BioMarin Pharmaceutical was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 3/25/2026 – BioMarin Pharmaceutical was upgraded by Truist Financial Corporation to “strong-buy”.
• 3/16/2026 – BioMarin Pharmaceutical had its “outperform” rating reaffirmed by Wolfe Research.
• 3/12/2026 – BioMarin Pharmaceutical had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $103.00 price target on the stock.
• 3/11/2026 – BioMarin Pharmaceutical had its price target lowered by Bank of America Corporation from $97.00 to $85.00. They now have a “buy” rating on the stock.

Insider Activity

In related news, EVP Gregory R. Friberg sold 6,326 shares of the firm’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $60.38, for a total transaction of $381,963.88. Following the transaction, the executive vice president directly owned 37,578 shares of the company’s stock, valued at $2,268,959.64. This trade represents a 14.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Charles Greg Guyer sold 16,486 shares of the company’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $60.46, for a total transaction of $996,743.56. Following the completion of the sale, the executive vice president directly owned 79,953 shares of the company’s stock, valued at $4,833,958.38. The trade was a 17.09% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.85% of the company’s stock.

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.